1.
HIV-1 pol gene polymorphism and antiretroviral resistance mutations in treatment-naïve adult patients in French Guiana between 2006 and 2012
by Darcissac, Edith
AIDS research and human retroviruses, 2016, Vol.32 (ja), p.801-811
2.
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT...
by Perez-Molina, José A, PhD
The Lancet infectious diseases, 2015, Vol.15 (7), p.775-784
3.
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcr...
by Arribas, José R, Dr
The Lancet infectious diseases, 2015, Vol.15 (7), p.785-792
4.
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
by Siliciano, Robert F
Nature medicine, 2008, Vol.14 (7), p.762-766
5.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
by Fellay, Jacques
The Lancet (British edition), 2002, Vol.359 (9300), p.30-36
6.
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected...
by Molina, Jean-Michel, Prof
The Lancet (British edition), 2008, Vol.372 (9639), p.646-655
7.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomise...
by Clotet, Bonaventura, Dr
The Lancet (British edition), 2007, Vol.369 (9568), p.1169-1178
8.
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
by ORTIZ, Roberto
AIDS (London), 2008, Vol.22 (12), p.1389-1397
9.
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomi...
by Molina, Jean-Michel, Dr
The Lancet infectious diseases, 2012, Vol.12 (1), p.27-35
10.
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
by MARTINEZ, Esteban
AIDS (London), 2010, Vol.24 (11), p.1697-1707
11.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomi...
by Eron, Joseph
The Lancet (British edition), 2006, Vol.368 (9534), p.476-482
12.
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
by MILLS, Anthony M
AIDS (London), 2009, Vol.23 (13), p.1679-1688
13.
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-...
by Cahn, Pedro, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.572-580
14.
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis
by AJOSE, Olawale
AIDS (London), 2012, Vol.26 (8), p.929-938
15.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled p...
by Madruga, José Valdez, Dr
The Lancet (British edition), 2007, Vol.370 (9581), p.49-58
16.
HIV protease inhibitor exposure predicts cerebral small vessel disease
by SOONTORNNIYOMKIJ, Virawudh
AIDS (London), 2014, Vol.28 (9), p.1297-1306
17.
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks i...
by Hicks, Charles B
The Lancet (British edition), 2006, Vol.368 (9534), p.466-475
18.
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)
by Stroppa, Elisa Maria
Future oncology (London, England), 2020, Vol.16 (20), p.1425-1432
19.
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
by Raffi, François
AIDS (London), 2015, Vol.29 (2), p.167-174
20.
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
by MARRA, Christina M
AIDS (London), 2009, Vol.23 (11), p.1359-1366
